Reports Q4 revenue $455M, consensus $445.36M. “We are very pleased with our results in 2023 with both revenues and operating margins exceeding expectations while continuing to make investments in key growth initiatives and M&A,” said Matt Trerotola, CEO. “We look forward to carrying this momentum into 2024, which is setting up to be a transformative year as we integrate Lima and kick off a multi-year cadence of new product introductions across Recon and P&R.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENOV:
- BTIG medical technology analyst to hold analyst/industry conference call
- ENOV Upcoming Earnings Report: What to Expect?
- Enovis initiated with an Overweight at Stephens
- Enovis™ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting
- Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
